BioMarck Pharmaceuticals
Durham, US · North Carolina corporation
Founders & leadership
RH
Robin HenningExecutive
BD
Brian DicksonExecutive
IP
Indu ParikhNamed on SEC filing
Board
TH
Thomas H. RobergBoard director
KC
Kennedy C. O'HerronBoard director
CA
Craig A. CollardBoard director
RK
Rajin K. AhujaBoard director
WL
Walker LongBoard director
MM
Mohit MehrotraBoard director
AC
Ashish C. BhatiaBoard director
LC
Laura Calamos NasirBoard director
Reported raises · per SEC filings
Form D private placements$7.8M disclosed across 2 rounds · 2013–2016
▶$751.3KraisedFeb 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$751.3KraisedFeb 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Indu ParikhExecutive Officer
- Craig A. CollardDirector
- Rajin K. AhujaDirector
- Kennedy C. O'HerronDirector
- Laura Calamos NasirDirector
- Mohit MehrotraDirector
- Thomas H. RobergDirector
- Walker LongDirector
- Brian DicksonExecutive Officer
- Ashish C. BhatiaDirector
- Michael EnrightExecutive Officer
- Offering amount
- $6M
- Amount sold
- $751.3K
- First sale
- Dec 2016
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$7MraisedMay 2016 · 7 investors · PharmaceuticalsRule 506(b)
▶$7MraisedMay 2016 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Indu ParikhExecutive Officer
- Thomas H. RobergDirector
- Kennedy C. O'HerronDirector
- Craig A. CollardDirector
- Robin HenningExecutive Officer
- Brian DicksonExecutive Officer
- Rajin K. AhujaDirector
- Walker LongDirector
- Mohit MehrotraDirector
- Ashish C. BhatiaDirector
- Laura Calamos NasirDirector
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Jul 2013
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $197.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $201.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has BioMarck Pharmaceuticals raised?
- BioMarck Pharmaceuticals has disclosed $7.8M raised across 2 rounds.
- Where is BioMarck Pharmaceuticals headquartered?
- BioMarck Pharmaceuticals is headquartered in Durham, US.